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Random-start controlled ovarian stimulation
KEY MESSAGE
New ovarian stimulation approaches, such as luteal/random start and double stimulation, are useful for meeting 
the double demands of optimizing flexibility in ovarian stimulation and improving IVF outcomes. Such protocols 
may be applicable for fertility preservation in cancer patients and for increasing oocyte yield in poor responders.
ABSTRACT
The theory of a multicyclic development of follicles during the menstrual cycle prompted new approaches to ovarian 
stimulation, such as starting gonadotrophins for ovarian stimulation at any time during the menstrual cycle or using 
double stimulation during it, with stimulation in both the follicular and luteal phases. Because of the asynchrony 
between endometrial receptivity and embryo development with a ‘non-conventional start’ stimulation, all the 
oocytes/embryos are generally cryopreserved and transferred subsequently. This deferred transfer policy is currently 
possible given the advances in vitrification techniques, with success rates comparable to those following transfer 
with ‘fresh’ embryos. New stimulation approaches, together with advanced cryopreservation techniques, allow for 
a total ‘disarticulation’ between the time of the menstrual cycle, ovarian stimulation start and embryo transfer. 
This new approach to ovarian stimulation is particularly useful for women seeking fertility preservation, especially 
where a shortened time to starting cancer treatment is desirable. Also, poor responders could benefit from the new 
stimulation protocols by continuing ovarian stimulation after the first oocyte retrieval, thereby obtaining more oocytes 
or embryos compared with the conventional approach.
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INTRODUCTION
An IVF treatment cycle consists of various stages: ovarian stimulation, mostly with gonadotrophins; use 
of gonadotrophin-releasing hormone 
(GnRH) agonists or antagonists for 
pituitary suppression, thereby avoiding 
premature ovulation; ovulation trigger 
for final oocyte maturation; timed 
oocyte retrieval; IVF of gametes; embryo 
culture and finally embryo transfer. 
Most current IVF programmes involve a 
fresh embryo transfer policy, with spare 
embryos frozen for subsequent use, 
either when the fresh cycle fails to result 
in a pregnancy or when couples want 
another child following a successful cycle. 
Ovarian stimulation is a fundamental 
part of IVF programmes, in which 
exogenous gonadotrophins are used to 
achieve supraphysiological levels during 
the period of follicular recruitment to 
override the process of dominant follicle 
selection and enable multiple follicular 
recruitment (Macklon, 2006). FSH is 
usually administered in the early follicular 
phase. The mean duration of stimulation 
is 11–12 days and in this period there is 
progressive growth of antral follicles, 
steroid production by the ovaries and 
endometrial proliferation. The object of 
stimulation is recruitment of multiple 
follicles in order to have many oocytes 
and increase the chances of pregnancy 
in IVF.
Recent research has suggested 
that recruitable antral follicles are 
continuously present in the ovaries 
during the menstrual cycle, and 
ultrasonographic studies have 
demonstrated that multiple cohorts or 
‘waves’ of 2–5 mm follicles are recruited 
continuously during a menstrual 
cycle (Baerwald, 2003a). A wave is a 
synchronous growth of follicles that 
have a similar diameter. Waves of follicle 
development have been documented in 
healthy women using ultrasonography 
(Baerwald, 2003b).
It has been proposed that there are 
two waves of follicular growth during 
the menstrual cycle. The first wave 
occurs in the follicular phase and 
a second wave in the luteal phase 
(FIGURE 1). Most women appear to exhibit 
two waves, with a minority exhibiting 
three waves. Women with three waves 
may have a longer menstrual cycle 
compared to women with two waves 
(Baerwald, 2003b). The inhibin B 
produced from the recruited cohort 
inhibits FSH secretion during the mid-
follicular phase. A second short peak 
of inhibin B is present after the LH 
surge, supporting the idea of a second 
wave of follicles during the luteal phase 
(Frachimont, 1975). The follicular wave 
that emerges in the early to mid-
follicular phase is ovulatory, while the 
wave or waves emerging in the luteal 
phase are usually anovulatory. Follicular 
waves are also present in women 
during perimenopausal transition 
(Hale, 2007) and in women undergoing 
ovarian stimulation (Bentov, 2010). The 
follicular waves could be recruited by 
constantly high concentrations of FSH. 
This new knowledge about ovarian 
function and, in particular, the theory 
of a multicyclic development of follicles 
during the menstrual cycle, resulted 
in the prospect of new approaches to 
ovarian stimulation and, in particular, 
the random-start ovarian stimulation 
protocols, namely the administration of 
exogenous gonadotrophins randomly on 
any day of the monthly menstrual cycle. 
In parallel with these new theories in 
ovarian stimulation protocols, advances 
in vitrification of embryos and oocytes 
has allowed important progress to 
be made towards a new concept of a 
total ‘disarticulation’ between ovarian 
stimulation and embryo transfer.
As a consequence, new ovarian 
stimulation protocols can be proposed 
to those patients who could potentially 
benefit. These are useful particularly 
in cases of oncology patients seeking 
fertility preservation who may present 
at any stage during the menstrual cycle 
(Cakmak and Rosen, 2013; von Wolff, 
2009). Adhering to the convention of 
initiating controlled ovarian stimulation 
at the beginning of the follicular phase 
may result in either significant delay of 
cancer treatments or foregoing fertility 
preservation because of time constraints. 
Of course, these new protocols may 
also be useful to women who want to 
preserve fertility for non-medical reasons, 
where double stimulation protocols might 
help with oocyte/embryo accumulation 
(Moffat, 2014; Tsampras, 2017). It has 
been suggested that double stimulation 
might serve as a useful strategy for 
poor ovarian response patients where 
accumulation of more oocytes in a 
short time could improve IVF outcomes 
(Cardoso, 2017; Kuang, 2014; Liu, 2017; 
Ubaldi, 2016).
This review article examines the evolution 
of new forms of ovarian stimulation 
due to expanding knowledge of ovarian 
physiology and discusses the implications 
of this strategy in clinical practice.
RANDOM- AND LUTEAL PHASE-
START OVARIAN STIMULATION 
PROTOCOLS
The need to start ovarian stimulation on 
any day of the menstrual cycle initially 
occurred in an oncology setting. Fertility 
preservation for cancer patients has 
become essential in oncology care. 
Cancer treatment (especially alkylating 
agents such as cyclophosphamide or 
total body irradiation prior to stem cell 
transplantation) is often cytotoxic and 
may result in depletion of ovarian follicles 
with subsequent subfertility and ovarian 
failure (Gracia, 2012; Letourneau, 2012). 
Ovarian stimulation for embryo or 
oocyte cryopreservation is the preferred 
method of fertility preservation in post-
pubertal girls and women with cancer 
and the only technique approved by 
the American Society for Reproductive 
Medicine (ASRM) (Ethics Committee 
of American Society for Reproductive 
Medicine, 2013). All other methods of 
fertility preservation, such as ovarian 
tissue cryopreservation, ovarian 
transplantation, in-vitro maturation 
of immature oocytes and the use of 
GnRH analogues are still considered 
investigational (Ethics Committee of 
American Society for Reproductive 
Medicine, 2013), although ovarian tissue 
cryopreservation is the only possibility 
when the cancer treatment cannot be 
postponed (Donnez, 2017). Traditionally, 
ovarian stimulation is initiated at the start 
of the follicular phase, but this method 
may require several weeks, depending 
on the patient’s menstrual cycle phase 
at the time of the initial visit. The theory 
of multiple follicular waves and hence 
the possibility of random-start ovarian 
stimulation is an attractive approach for 
cancer patients. In cancer patients, there 
is no need to achieve synchrony between 
ovaries and endometrium as there is 
no fresh embryo transfer, thus allowing 
random-start stimulation protocols.
Luteal phase- and random-start protocols 
have also recently been applied outside 
the oncological setting, in normal and 
poor responders.
Luteal phase protocols initiate ovarian 
stimulation between days 15 and 20 
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of the menstrual cycle (FIGURE 2). The 
largest study on luteal phase stimulation 
was performed by Wang et al. (2016) 
on normal responder patients. They 
compared three protocols: short 
agonist protocol, mild stimulation 
with clomiphene or letrozole followed 
by 225 IU of human menopausal 
gonadotrophin (HMG) and luteal 
stimulation with 225 IU of HMG. 
Implantation rates were identical with 
luteal stimulation (35.5%, N = 727) and 
mild stimulation (34.8%, N = 830), 
but significantly lower with the 
standard short agonist protocol (31.8%, 
N = 1385, P = 0.012). The same group 
demonstrated in a retrospective study 
that the luteal stimulation (clomiphene 
then HMG beginning at day 1 or 2 
post-ovulation) was associated with a 
significantly higher number of oocytes 
collected and top-quality embryos 
(2.8 versus 2.0, P < 0.05 and 0.9 versus 
0.4, P < 0.05, respectively) compared 
with conventional-start stimulation 
(clomiphene then HMG beginning at 
day 3 with a flexible antagonist) but also 
significantly longer ovarian stimulation 
and higher dose of HMG required. 
This study has some limitations: it is a 
FIGURE 1 The wave theory of follicle recruitment suggests that two or more waves of antral follicles emerge during the ovarian cycle. In women 
with two follicular waves (a), an anovulatory wave emerged at the early luteal phase followed by emergence of the ovulatory wave during the early 
follicular phase. In women with three waves (b), an anovulatory wave emerged at the time of ovulation (ov), a second anovulatory wave emerged 
during the mid to late luteal phase and the ovulatory wave emerged in the early to mid-follicular phase. The dominant follicle develops in a minority 
of anovulatory waves. Follicle ‘cyclic recruitment’ is the process by which a single ‘dominant’ follicle is chosen from the recruited cohort or wave 
for preferential growth (modified with permission from Baerwald et al., 2012).
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retrospective study and the number 
of retrieved oocytes (5.9–6.6) appears 
very low for normoresponder patients 
(Li, 2016).
To date few studies have been published 
reporting the efficacy of random-start 
protocols. However, preliminary results 
indicate that the number of total and 
metaphase II oocytes retrieved and 
fertilization rates are similar in early 
follicular and random-start protocols. 
Random-start ovarian stimulation 
results in a similar length of ovarian 
stimulation and in similar gonadotrophin 
use. ‘Random-start’ control ovarian 
stimulation protocols were reported to 
be successful in women with cancer who 
started stimulation on menstrual cycle 
days 11, 14 or 17 (Sönmezer, 2011). In 
three patients with a diagnosis of breast 
cancer requiring emergency fertility 
preservation in the late follicular or luteal 
phase of the menstrual cycle, random-
start ovarian stimulation was commenced 
immediately on menstrual cycle days 
11, 14 or 17 with use of letrozole 2.5 mg/
day and recombinant FSH 150–300 IU/
day (Sönmezer, 2011). In another study, 
in a 27-year-old woman with Hodgkin 
lymphoma, ovarian stimulation was 
performed with recombinant FSH 450 IU 
starting on day 11 of the menstrual cycle 
(Ozkaya, 2012). GnRH antagonist was 
administered to prevent ovulation in 
all four cases. Ovulation was triggered 
with either 250 mg of recombinant 
HCG, 10,000 IU of urinary HCG or 
0.1 mg of leuprolide acetate. Nine to 31 
oocytes were obtained, resulting in a 
good number of embryos to be frozen 
(Ozkaya, 2012; Sönmezer, 2011).
This approach resulted in a considerable 
number of oocytes and embryos. 
Also, the ovary with corpus luteum 
showed a similar number of dominant 
follicles compared with the patient’s 
contralateral ovary on the day of the 
trigger (Ozkaya, 2012). Of course, the 
random-start ovarian stimulation can 
also be proposed in an IVF setting, for 
example in oocyte donors and in clinics 
that practise ‘freeze all’ almost routinely 
due to the use of clomiphene citrate 
to reduce the cost of attempts. In the 
study by Qin and colleagues (2016), 
ovarian stimulation in infertile women 
prior to IVF was started independently 
of the day of the menstrual cycle. A 
total of 150 women were treated and 
ovarian stimulation was started in the 
early, late follicular or luteal phase. 
Flexibility in starting stimulation at any 
day of menstrual cycle stems from the 
fact that patients in China come from 
many different districts, in different 
phases of the menstrual cycle and wish 
to commence infertility therapy as soon 
as possible. There were no differences 
in the mean number of mature oocytes 
retrieved in the conventional group, late 
follicular phase group and luteal phase 
group (5.7 ± 3.6, 5.2 ± 3.7 and 5.2 ± 3.9, 
respectively). In the subsequent frozen 
embryo transfer cycles, the clinical 
pregnancy rates (41.5%, 45.5% and 
38.9%), and implantation rates (30.7%, 
30.2% and 27.1%) were similar in the 
three groups (Qin, 2016). At the moment 
it remains quite difficult to translate these 
preliminary studies to routine clinical 
practice because of the low number of 
patients, the heterogeneity of groups 
and the fact that they are retrospective 
studies.
DOUBLE OVARIAN STIMULATION 
(DOS) REGIMEN
The concept of continuous ovarian 
follicular growth, random start of ovarian 
stimulation and the disarticulation of 
stimulation and embryo transfer led to 
the possibility of performing consecutive 
ovarian stimulation cycles and oocyte 
retrieval procedures in order to increase 
the number of oocytes available (and 
possibly embryos) per patient in one 
given cycle.
DOS consists of two successive ovarian 
stimulations in the follicular and ensuing 
luteal phase with two oocyte retrievals 
at the end of both ovarian stimulations 
(FIGURE 3A).
The efficacy of a DOS during the 
follicular and luteal phase was reported 
for the first time a few years ago (Kuang, 
2014) (TABLE 1). Use of a second ovarian 
stimulation during the luteal phase was 
first applied in poor responder patients: 
for patients who respond poorly to 
FIGURE 2 The FSH threshold and window in a spontaneous, conventional ovarian stimulation and luteal-start ovarian stimulation cycle. During the 
luteal phase a longer FSH window permits multiple follicular growth.
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gonadotrophin stimulation various 
treatment protocols have been used as 
patient-friendly techniques to optimize 
the relationship between safety and 
success (Loutradis, 2003; Ubaldi, 2005) 
but the prognosis in these patients 
remains poor, with a live birth rate of 
6.8–7.9% (Ferraretti and Gianaroli, 2014; 
La Marca, 2015; Polyzos, 2014).
Kuang et al. (2014) tested the possibilities 
of two ovarian stimulations during 
the follicular and luteal phase and 
showed good results in terms of more 
opportunities for retrieving oocytes. 
In these regimens the first stimulation 
started normally in the early follicular 
phase, while the second stimulation 
started on the first day after the first 
oocyte retrieval on which two or more 
antral follicles were identified. The 
trial was conducted in 38 patients 
who all fulfilled the Bologna criteria 
for poor responders, based on prior 
ovarian stimulation outcome, baseline 
hormonal levels and age. The first and 
second stimulations used two different 
regimens as follows: the first stimulation 
was conducted using a combination 
of clomiphene citrate 25 mg per day 
starting on day 3 of the cycle until the 
triggering of ovulation, letrozole 2.5 mg 
per day starting on day 3 for a total of 
4 days and HMG 150 IU every other day, 
starting on day 6 until the triggering of 
ovulation. The second stimulation was 
FIGURE 3 (a) Double stimulation regimens: two successive ovarian stimulations with two oocyte retrievals at the end of both ovarian stimulations 
are performed in less than 1 month. The first ovarian stimulation starts during the early follicular phase and the second can begin the day after the 
first oocyte retrieval. (b) Double randomly started ovarian stimulation (DoubleRandom-OS): two successive ovarian stimulations with two oocyte 
retrievals at the end of both ovarian stimulations are performed in approximately 25 days. The first ovarian stimulation can start randomly during 
the menstrual cycle (e.g. during the luteal phase), and the second can begin the day after the first oocyte retrieval. If ovarian stimulation starts 
during the luteal phase normally after some days of gonadotrophin therapy menstruation occur.
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started after the first oocyte retrieval, 
provided that two or more antral follicles 
were identified. This stimulation regimen, 
which differed from the first stimulation, 
consisted of letrozole 2.5 mg and HMG 
(225 IU/day), which were both started 
from the day of retrieval until the second 
triggering of ovulation. For both the first 
and second stimulations, final oocyte 
maturation was induced with triptorelin 
when follicular maturation was reached.
The first and second stimulations 
provided a similar number of oocytes and 
embryos. From the double stimulation, 
more than half of patients produced 
one to six viable embryos cryopreserved 
for later embryo transfer cycles with 
good implantation and pregnancy 
rate, indicating that embryos derived 
from double stimulation have similar 
development potential (Kuang, 2014).
Moffat et al. (2014) commented that 
their preliminary data appeared to 
confirm Kuang’s findings: a second 
ovarian stimulation started immediately 
TABLE 1 SUMMARY OF RESULTS OF STUDIES ON DOUBLE OVARIAN STIMULATION.
Author Type of 
study
















Pilot study Poor 
responders




 letrozole  
2.5 mg daily + 
HMG + GnRH 
 antagonist  
GnRH agonist 
triggering
10.2 ± 2.4 326 ± 248 1.7 ± 1 1 ± 1 48 (11/23)





+ MPA. GnRH 
 agonist  
triggering







42 First ovarian 
stimulation
FSH 300 IU 





9.6 ± 2.4 na 5.1 ± 3.4 2.3 ± 1.7 85.7 (6/7)a
42 Second  
ovarian 
 stimulation
FSH 300 IU 





10.3 ± 2.5 na 5.7 ± 3.3 3.2 ± 2.3 75 (6/8)a











FSH 225 IU + 
HMG 75 IU 




na na 11.7 (range 
1–28)
na na






116 First ovarian 
stimulation
Short GnRH 







8.2 ± 3.5 1882 ± 958 2.33 ± 1.99 1.66 ± 1.47 25
116 Second  
ovarian 
 stimulation
HMG 225 IU. 
HCG  
triggering
7.5 ± 3.3 1728 ± 937 3.5 ± 3.55 2.4 ± 2.7 20.59




10 First ovarian 
stimulation
HMG 150–450 





na 8.1 (range 1–13)na na









na 8.2 (range 
1–19)
na na
Data are mean ± SD unless otherwise indicated.
GnRH = gonadotrophin-releasing hormone; HCG = human chorionic gonadotrophin; HMG = human menopausal gonadotrophin; MPA = medroxyprogesterone acetate; 
na = not available.
a per euploid blastocyst transfer.
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after a first oocyte retrieval provided 
as many oocytes and blastocysts as 
obtained in the first ovarian stimulation. 
In this experience, both the first and 
second stimulations used a classical 
antagonist protocol with 300 IU of FSH 
per day, cetrorelix 0.25 mg starting on 
ovarian stimulation day 6 and GnRH 
trigger (triptorelin 0.2 mg) when follicular 
maturation was reached. The first 
and second stimulations provided a 
similar number of oocytes, zygotes and 
blastocysts, doubling the final blastocyst 
yield, compared with a classical single 
ovarian stimulation assisted reproductive 
technology cycle (Moffat, 2014).
Ubaldi et al. (2016) recently confirmed 
that both follicular phase and consecutive 
luteal phase stimulation resulted in a 
similar number of oocytes and embryos. 
Patients with reduced ovarian reserve 
started follicular stimulation on day 2 of 
the menstrual cycle with rFSH and 75 IU 
of recombinant LH. Daily administration 
of a GnRH antagonist was started when 
the leading follicle was 13–14 mm in 
diameter and continued until the day 
of trigger of ovulation. When at least 
two follicles had reached 17–18 mm 
in diameter, ovulation was triggered. 
Five days after the first oocyte retrieval 
a second gonadotrophin stimulation 
was started with the same stimulation 
protocol. In both follicular and luteal 
phase stimulation, ovulation was triggered 
with buserelin and oocyte retrieval was 
performed after 35 h. No statistically 
significant differences were found 
in the number of retrieved oocytes, 
MII oocytes, blastocysts or euploid 
blastocysts between the two stimulation 
cycles (Ubaldi, 2016). The rate of 
euploid embryos increased from 41.9%, 
considering only that obtained from the 
first stimulation, to 69.8% with oocytes 
obtained from both follicular and luteal 
phase stimulation.
More recently, three studies confirmed 
that two subsequent ovarian stimulations 
during the same month may maximize 
the number of gametes obtained 
(Cardoso, 2017; Liu, 2017; Tsampras, 
2017).
Cardoso et al. (2017) analysed the 
performance of double stimulation in 
13 patients that underwent a previous 
unsuccessful IVF cycle. First and second 
stimulations were performed with the 
same protocol using a high dose of 
gonadotrophins (225 IU rFSH and 75 IU 
HMG) in an antagonist protocol. The 
second stimulation started 5 days after 
the first oocyte pick-up with a GnRH 
agonist triggering. The mean number of 
oocytes collected increased from 6.7 in 
the previous standard follicular phase-
start cycle to 11.7 with DOS.
In the study by Liu and colleagues 
(2017), 116 women aged 38 years or older 
were divided into four groups according 
to their ovarian stimulation protocols 
of the follicular phase, including GnRH 
agonist short protocol, GnRH antagonist 
protocol, mild stimulation protocol 
and progestin pituitary down-regulation 
protocol. The subsequent luteal phase 
stimulation was performed with 225 IU 
HMG daily within 1–3 days of oocyte 
retrieval. Both triggerings were done with 
250 IU rHCG. The number of oocytes 
retrieved (5.83 ± 4.60), MII oocytes 
(4.73 ± 4.01) and cleaved embryos 
(4.00 ± 3.42) in double stimulation 
were increased and the cancellation 
rate of no available embryos reduced 
(37.07% versus 18.10%) significantly 
compared with standard follicular phase 
stimulation.
Double stimulation could be useful also 
for patients with unexpected suboptimal 
response in the follicular phase, due 
to insufficient gonadotrophin dose. If 
the clinician identifies a suboptimal 
response during ovarian monitoring, one 
possibility is to stop the cycle and start 
again with higher gonadotrophin starting 
dose; the other is to move on and 
perform a second stimulation in case of 
insufficient oocyte retrieval after the first 
stimulation.
Finally, DOS was tested in oncological 
patients. Patients diagnosed with a 
malignancy commenced a random-
start antagonist stimulation protocol. 
The initial dose of gonadotrophin was 
between 150 and 450 IU of HMG. 
The final maturation of oocytes was 
triggered by 5000 IU of HCG. On 
the day of oocyte collection, the 
patients were offered the option of a 
second stimulation starting the same 
day or after a few days. The dose 
of gonadotrophin was the same or 
increased, depending on the ovarian 
response in the first stimulation cycle. 
This pilot study demonstrated an 
increase in number of mature oocytes 
retrieved with DOS for oncology 
patients, without delaying cancer 
treatment (Tsampras, 2017).
According to the Tsampras study, 
the double randomly started ovarian 
stimulation (referred to here as 
double random ovarian stimulation) is 
particularly interesting and beneficial for 
cancer patients because it allows more 
oocytes for fertility preservation in a 
short period of time compared with a 
conventional-start stimulation protocol 
(FIGURE 3B).
In our clinic we usually start ovarian 
stimulation in oncological patients 
regardless of the menstrual phase. 
If the patient with cancer presents, 
at the latest, at the fourth or fifth 
day of the menstrual cycle and no 
follicles are recruited, we start ovarian 
stimulation the same day. If the patient 
presents in the follicular phase with a 
dominant follicle larger than 14 mm 
we wait for spontaneous ovulation 
to start stimulation or GnRH agonist 
is administered to trigger ovulation. 
If the patient presents in the luteal 
phase ovarian stimulation is started 
immediately. Ovarian stimulation is 
performed using recombinant FSH or 
HMG, at a dose of at least 200 IU. On 
day 5–6 of the stimulation an ultrasonic 
evaluation of the number and size of 
ovarian follicles is performed. GnRH 
antagonist is started to prevent LH surge 
when the lead follicle measures over 
14 mm and continues until the GnRH 
agonist triggers final oocyte maturation. 
Triggering of final oocyte maturation is 
performed as soon as three follicles of 
≥ 17 mm diameter are present. Thirty-six 
hours after triggering oocyte retrieval is 
performed by ultrasound-guided vaginal 
follicle aspiration. The oocytes collected 
are cryopreserved by vitrification. The 
second ovarian stimulation starts the 
day after the first oocyte pick-up with 
the same dose and drug used in the first 
one. Monitoring of ovarian response in 
the second ovarian stimulation is more 
difficult due to the presence of corpora 
lutea. Similar to the first stimulation, 
antagonist is started when the lead 
follicle reaches 14 mm and triggering 
of final oocyte maturation is performed 
as soon as three follicles of ≥ 17 mm 
diameter are present by GnRH agonist. 
The second pick-up is more difficult than 
the first due to the major risk of bleeding 
from the corpora lutea. This second 
batch of oocytes is also cryopreserved by 
vitrification.
Although many authors use GnRH 
antagonist during both follicular and 
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luteal phase stimulation (Cardoso, 2017; 
Tsampras, 2017; Ubaldi, 2016), it could 
be assumed that agonist or antagonist 
is not necessary in the luteal phase 
and that endogenous progesterone 
alone is sufficient to block the LH 
surge. Some studies conducted on 
luteal phase stimulation or double 
stimulation have demonstrated that the 
risk of ovulation is not increased by the 
absence of agonists or antagonists in 
the luteal phase stimulation (Li, 2016; 
Liu, 2017; Massin 2017; Wang, 2016a). 
It is reasonable to think that during 
luteal phase stimulation, both in a 
spontaneous cycle and subsequent to a 
follicular phase stimulation, the use of 
agonist or antagonist is useless and can 
only raise patient discomfort, especially 
in oncological patients, but this point 
needs to be clarified. In our clinic we 
continue to use the GnRH antagonist 
during the second stimulation, while we 
await further scientific evidence about 
the efficacy of endogenous progesterone 
alone in preventing LH surge.
DISCUSSION
The recognition of multiple waves of 
follicle development during the menstrual 
cycle provides a new model for 
understanding human ovarian follicular 
development. These observations suggest 
the possibility that ovarian follicles 
are available for ovarian controlled 
stimulation throughout the menstrual 
cycle independently of gonadotrophin 
fluctuation and that the resulting 
oocytes are mature and competent for 
fertilization.
Several studies (Li, 2016; Qin, 2016; 
Wang, 2016) indicate that ovarian 
stimulation can be completely 
disconnected from the menstrual cycle 
with no impact on implantation rate if no 
fresh embryo transfer takes place.
Because of the asynchrony between 
endometrial receptivity and embryo 
development in cases of a ‘non-
conventional start’ stimulation, 
all the oocytes/embryos have to 
be cryopreserved and transferred 
subsequently. The technique of 
vitrification has been widely employed in 
recent years at the expense of the more 
traditional approach of cryopreservation 
by slow cooling. Using vitrification, 
cryopreserved embryo transfers have 
the same implantation potential as 
fresh embryo transfers because of high 
survival rates of embryos, which implant 
at the same rate as equivalent fresh 
counterparts (Edgar and Gook, 2012).
The possibility of starting ovarian 
stimulation on any day of the menstrual 
cycle and the fact that pregnancy 
rates associated with vitrified-warmed 
embryos are comparable with those 
after fresh embryo transfer allow a 
total disarticulation among menstrual 
cycle, ovarian stimulation and embryo 
transfer. This could be a useful tool 
for the clinician in order to satisfy the 
double demands of optimizing flexibility 
in ovarian stimulation and improving 
outcomes in IVF. DOS, consisting of 
two successive ovarian stimulations in 
the follicular and ensuing luteal phase, 
is a viable option when insufficient 
ovarian response to gonadotrophins is 
expected. Moreover, the short overall 
duration of these approaches (<30 
days) is valuable for cases of fertility 
preservation in which the largest 
number of oocytes is desirable. In 
these cases the double stimulation may 
be randomly started (double random 
ovarian stimulation).
DOS appears to be useful, but its role 
in all categories of patients should be 
investigated. Obviously, the cost of the 
IVF cycle with two ovarian stimulations 
and two oocyte retrievals is higher 
due to the increasing working hours of 
doctors and biologists, higher number of 
units of gonadotrophins used, increased 
workload for the laboratories and the 
cost of vitrification. Furthermore, the 
switch from fresh embryo transfers to 
vitrified-warmed embryo transfers will be 
an extra cost for the couple. It follows 
that clinicians have to carefully choose 
patients who would benefit from double 
stimulation regimens (Maheshwari, 2018).
In contrast, time to pregnancy, 
particularly in women with low ovarian 
reserve, could be lower because of 
the short time (<30 days) in which an 
adequate number of oocytes is retrieved. 
Furthermore, adherence of patients to 
repeated ovarian stimulation within one 
cycle could be higher, because patients 
may be less likely to abandon the IVF 
treatment before the embryo transfer 
has been performed. In fact, after a first 
IVF, especially if the response has been 
very poor, the probability of withdrawal 
from IVF treatment is very high (Brandes 
et al., 2009).
Certain problems with DOS remain 
unsolved: firstly, it is not known which 
is the best day to start the second 
stimulation. All studies reported an 
interval of 1–5 days without significant 
difference in terms of length of 
stimulation and number of oocytes 
retrieved. There is no scientific basis to 
choose the duration of interval between 
first pick-up and the start of the second 
ovarian stimulation. It is also not known 
what the ideal drug is for triggering: 
some authors have reported successful 
pick-up with the use of HCG even in the 
first stimulation while the majority used 
GnRH agonist triggering. The utility of 
using a higher dose of gonadotrophin in 
the second stimulation or an LH activity 
drug is still under investigation.
In summary, other studies are needed 
to evaluate the efficacy of these new 
strategies of ovarian stimulation to 
improve outcomes of women with poor 
prognosis in IVF or that need the highest 
numbers of oocytes or embryos in the 
shortest time.
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